Maravai is a holding company. Through its subsidiaries, Co. operates as a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases. Co.'s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. Co. operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The MRVI stock yearly return is shown above.
The yearly return on the MRVI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MRVI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|